Board of Directors
Jay Lichter, PhD
Chairman, President and Chief Executive Officer
Jay Lichter, PhD, is an entrepreneur and seasoned investor in the biotechnology and pharmaceutical arena with over 25 years of expertise in management, scientific research, and business development.
As managing director of Avalon Ventures, Dr. Lichter led investments in SynthoRx, Afraxis, Carolus, Otonomy, Sova and Zacharon Pharmaceuticals. Dr. Lichter has served as CEO of many these companies, including Avelas Biosciences, which has included leading both their business and scientific operations. Dr. Lichter is on the board of directors for most of these companies and also served as Chairman of the Board of RQx, another Avalon company. He led the first life science investments for the Avalon IX portfolio, Sova Pharmaceuticals, and serves as its CEO and board member. He also led the investment in Aratana Therapeutics, where he serves as Chairman of the Board. Dr. Lichter is the inventor on over 260 patent and patent applications for six Avalon portfolio companies, including 78 issued patents. Dr. Lichter has been involved in licensing or merger and acquisition deals valued in excess of $3 billion.
Dr. Lichter held postdoctoral positions in Human Genetics at Yale University and pharmacogenetics at DuPont Merck Pharmaceutical Co. Dr. Lichter obtained his Ph.D. in biochemistry from the University of Illinois at Chicago, and a B.S. from the Univ. of Illinois at Urbana-Champaign.
Claus Kremoser, PhD
Claus Kremoser, Ph.D. joined Avelas Biosciences’ board of directors in May 2015. Dr. Kremoser is the co-founder and CEO of Phenex Pharmaceuticals AG. In December 2014 Phenex executed a $470 million transaction with Gilead Sciences on Phenex’s FXR NASH program. In addition, Dr. Kremoser has led numerous drug discovery partnerships for Phenex as well as implementing proprietary drug discovery programs on the targets RORgt and FXR.
Previously Dr. Kremoser served as Vice President of Corporate Development for LION Biosciences. He also served as a founding member of the German E&Y Life Science Practice where he co-authored the fourth and fifth editions of the European E&Y Biotech Report. He is currently a member of the BioRN board (Biotech Cluster Heidelberg) and communicates the benefits of combining science and entrepreneurship into “biobusiness”. Together with other leading German CEOs he is member of the “1% for the future” which aims in fostering political initiatives to build a new financing environment for high tech innovation in Europe and Germany.
Dr. Kremoser studied biochemistry at the Universities of Tübingen and Munich. He performed his Ph.D. thesis in the group of Dr. Friedrich Boenhoeffer at the Max-Planck Institute. Dr. Kremoser received his Ph.D. magna cum laude from the University of Tübingen.
Timothy Scott is co-founder and CEO of TEGA Therapeutics, a glycobiology company focused on lysosomal storage disorder and recombinant heparan sulfates. He previously was founder and President of Pharmatek Laboratories, a contract development and manufacturing company (sold to Catalent Pharma Solutions in 2016). Prior to that, Mr. Scott was Senior Vice President at Active.com. He previously served on the board of Zacharon Pharmaceuticals, which was sold to Biomarin 2014. He is a member of the boards of BIOCOM, a non-profit organization supporting the needs of bio/pharma companies in California, and CONNECT, a non-profit helping to create and scale innovation companies in San Diego. At UC San Diego, he serves on the Dean’s Advisory Council for the Division of Biological Sciences. Mr. Scott earned his B.A. in Biochemistry from the University of California, San Diego. He earned his J.D. from the University of San Diego and is a member of the California Bar.
Alexey Vinogradov, PhD
Alexey Vinogradov is a head of Pharmstandard Ventures (formerly Inbio Ventures). He has over 15 years of experience in various positions in the biotech industry. He is a director of four publicly-traded companies: Argos Therapeutics, Protagonist Therapeutics, Aquinox Pharmaceuticals, and Allena Pharmaceuticals. He also currently serves as a board member for Tear Solutions, Inc. Prior to joining Inbio Ventures in 2012 as co-founding partner and CBO, Dr. Vinogradov played active role in portfolio building at Bioprocess Capital Partners where he led the fundraising and served on the executive management teams of Promogene, Tartis-Oncology and Everon. Dr. Vinogradov held a postdoctoral position at the Laboratory of Biomolecular Sciences, Wageningen University, Netherlands. He obtained his Ph.D. degree in Biochemistry and M.S. degree in Chemistry from Moscow State University.
Carmine Stengone is the President and Chief Executive Officer of Pipeline Therapeutics. Prior to joining Pipeline, Mr. Stengone served as Avelas’ President and Chief Executive Officer. Mr. Stengone joined Avelas in 2012 as Chief Business Officer, and has served as a Director since 2014. Mr. Stengone previously served as Senior Vice President, Business Development for COI Pharmaceuticals, where he helped co-found five new biotech companies, including Afraxis, Inc. Before that, Mr. Stengone was with Phenomix Corporation as the Senior Director of Business Development, and previously held positions of increasing responsibility at Anadys Pharmaceuticals and Johnson & Johnson Pharmaceutical Research and Development. Mr. Stengone received his MBA from the Johnson Graduate School of Management at Cornell University, his M.S. degree in organic chemistry from Duke University, and a B.S. in chemistry from Wake Forest University.